Noticias de CRL_US
Noticias del mercado
Últimas noticias sobre CRL_US — 264 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Charles River Laboratories International (CRL) just rolled out rapid cell banking programs built around Next-Generation Sequencing and its Pathoquest acquisition, aiming to shorten development timelines for advanced therapies and strengthen quality and regulatory control. For context, Charles River Laboratories International has seen strong momentum build over the past few months, with a 90-day share price return of 52.25% and a 1-year total shareholder return of 79.42%. These figures point...
Charles River Labs stock closed at USD 281.70 on September 17, 2026, up 3.0 percent after the launch
Charles River Laboratories International (NYSE:CRL) unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools. The platform is designed to shorten biologics and advanced therapy cell bank lead times for biopharma clients while supporting regulatory readiness. Charles River states that the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The new rapid cell banking and release...
Página 10 de 14